BiotechTube
TikkunLev Therapeutics

TikkunLev Therapeutics

New York, United States· Est.
tikkunlev.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

TikkunLev Therapeutics is a preclinical biotech focused on revolutionizing heart failure treatment through regenerative medicine. Its lead program, TLT-101, is a precision therapy derived from stem cell technology, designed to be administered as a one-time low IV dose and guided by a blood-based biomarker. The company boasts a strong scientific foundation from its co-founder's academic research and has assembled a leadership team and scientific advisory board with deep expertise in cardiology, gene therapy, and biotech development to advance its novel therapeutic paradigm.

Cardiovascular DiseaseHeart Failure

Technology Platform

Stem cell-derived biologic therapy platform coupled with a companion blood-based biomarker for precision patient selection.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The massive, growing global heart failure market represents a multi-billion dollar opportunity for a disease-modifying therapy.
A one-time, low-dose IV regenerative treatment with a companion diagnostic biomarker could achieve rapid adoption, premium pricing, and establish a new standard of care, positioning the company as a leader in precision cardiology.

Risk Factors

The company faces high scientific risk in translating preclinical stem cell biology to human efficacy, significant financial risk as a pre-revenue entity requiring large capital infusions, and intense competition from large pharmaceutical companies and other biotecs pursuing heart failure treatments.

Competitive Landscape

TikkunLev competes in the crowded heart failure therapeutic space dominated by large pharma (Novartis, AstraZeneca, etc.) but aims to differentiate with a regenerative, potentially curative approach. It faces competition from other biotechs exploring cell therapies, gene therapies, and novel biologics for cardiac repair, though its precision biomarker strategy may provide a unique edge.

More companies in Biologics / Biosimilars →More companies in United States →